The BIOTECH SUMMIT AUSTRIA 2024 in Innsbruck brought together leaders, innovators and investors to network, interact and to enjoy being part of the booming Austrian biotech community. It showcased science, funding and collaboration opportunities, setting the stage for 2025 in Graz.
RNA specialist ProQR Therapeutics NV bags US$8.1m funding
Latest NewsRNA editing specialist ProQR Therapeutics NV has deepened its collaboration with the Rett Syndrome Research Trust, which extented its funding of the preclinical MECP2 inhibitor AX-2402 to US$9.1m to speed up the translation to clinical trials.
Breakthroughs honoured: 2024 Nobel Prizes
Latest NewsAs part of the 2024 Nobel Prize Week, the prestigious awards have been presented. These include the Nobel Prize in Medicine or Physiology for the discoverers of microRNAs as a new class of regulatory molecules, and the Nobel Prize in Chemistry for AI-supported methods in protein design and the rapid calculation of their structures.
Noema Pharma AG extends Series B financing
Latest NewsSwiss Noema Pharma AG has cashed in a CHF27m extention to its Series B financing that is used to advance four Phase II programmes in neurology.
BIOTECH SUMMIT AUSTRIA: Seed to succeed
AssociationsThe BIOTECH SUMMIT AUSTRIA 2024 in Innsbruck brought together leaders, innovators and investors to network, interact and to enjoy being part of the booming Austrian biotech community. It showcased science, funding and collaboration opportunities, setting the stage for 2025 in Graz.
Citryll BV raises €85m in Series B financing
Latest NewsDutch inflammation specialist Citryll BV has raised €85m to push clininal testing of its lead candidate, CIT-013, a bifunctional antibody that prevents the release of neutrophil extracellular traps (NETs) from neutrophil granulocytes into the cytoplasm, thus blocking inflammatory and autoimmune diseases at its very roots.
Dewpoint Therapeutics and Mitsubishi Tanabe partner on ALS therapy
Latest NewsDewpoint Therapeutics Inc and Mitsubishi Tanabe Pharma Corporation have formed a collaboration, valued at up to $480m, to develop a novel small molecule condensate modulator for ALS, leveraging groundbreaking European research in condensate biology.
UK first country in Europe to reimburse tirzepatide
Latest NewsThe British NICE has defined the conditions for the reimbursement of Eli Lilly’s obesity blockbuster tirzepatide. This makes the UK the first country in which patients do not have to pay for the drug out of their own pocket.
French Ipsen inks US$610m biobucks deal with Biomunex SA
Latest NewsFrench Ipsen has exclusively licensed BMX-502, a T-cell engager (TCE) from Biommunex SA, which prevents common problems of TCEs such as cytokine release syndrome and T cell exhaustion by using a specific mucosal T cell subpopulation abundant in the human body.
Obesity gene therapy enters Phase I testing
Latest NewsAfter securing an equity investment from French pharma giant Sanofi, Italian gene therapy company Resalis Therapeutics srl has begun enrolling participants for a Phase I study of its obesity gene therapy, RES-010, which converts white adipocytes into brown adipocytes.
European Biotechnology and SLAS seal partnership
Background, Latest NewsThe Society for Laboratory Automation & Screening (SLAS) has selected the European Biotechnology Magazine as its official media partner.